Orelabrutinib: all 84 studies that test it

Page 1 of 1. Open to participants first (56), then studies with results posted, then the rest; newest registration first within each.

• Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)Not yet recruitingNCT07875972Phase 1
• A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Phase 3
• A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingNCT07719855Phase 3
• Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)RecruitingNCT07719556Phase 2
• Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell LymphomaNot yet recruitingNCT07677813Phase 2
• A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and LenalidomideNot yet recruitingNCT07585747Phase 2
• Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingNCT07554898Phase 2
• Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
• Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
• Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
• PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.RecruitingNCT07410520Phase 2
• Phase II Study of Orelabrutinib in Combination With Romiplostim N01 in Patients With Primary Immune Thrombocytopenia (ITP) Who Have Received At Least One Prior Line of TherapyNot yet recruitingNCT07400250Phase 2
• Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone LymphomaRecruitingNCT07355699Phase 4
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisRecruitingNCT07299019Phase 3
• Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingNCT07272499Phase 2
• Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaRecruitingNCT07257510Not applicable
• Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingNCT07208981Phase 2
• Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT AssessmentNot yet recruitingNCT07206264Phase 2
• Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRecruitingNCT07199296Phase 2
• A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）RecruitingNCT07191431Not applicable
• Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSLRecruitingNCT07185373Phase 2/3
• A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRecruitingNCT07067463Phase 3
• Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL PatientsNot yet recruitingNCT06901999Phase 2
• MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
• Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialRecruitingNCT06700798Phase 2
• A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell LymphomaNot yet recruitingNCT06656221Phase 2
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）RecruitingNCT06647940Phase 2
• Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaRecruitingNCT06566807Phase 2
• Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
• A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
• Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
• The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Phase 2
• Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
• A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi MonotherapyNot yet recruitingNCT06476899Phase 2
• Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
• ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Phase 2/3
• A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Phase 3
• Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Phase 3
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell LymphomaRecruitingNCT05933967Phase 2
• Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System InvolvementRecruitingNCT05926427Phase 2
• Pro-miniCHOP-like Regimen for Treatment-naive Elderly PatientsRecruitingNCT05809180Not applicable
• The Study of ICP-248 in Patients With Mature B-cell MalignanciesRecruitingNCT05728658Phase 1
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus ErythematosusRecruitingNCT05688696Phase 2
• Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy SubjectRecruitingNCT05684653Phase 1
• Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
• A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to IbrutinibRecruitingNCT05491044Phase 2
• Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSLRecruitingNCT05390749Phase 2
• Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell LymphomaNot yet recruitingNCT05381506Phase 2
• Genotype-guided Treatment in DLBCLRecruitingNCT05351346Phase 3
• Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System LymphomaRecruitingNCT05334238Phase 3
• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell LymphomaRecruitingNCT05234684Phase 3
• Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System LymphomaRecruitingNCT05209620Phase 2
• Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)RecruitingNCT04989621Phase 2
• Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System LymphomaRecruitingNCT04961515Phase 2
• ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
• Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZLActive, not recruitingNCT07480863Phase 2
• Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT LymphomaActive, not recruitingNCT06583837Phase 2
• Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy SubjectsStatus unknownNCT05660720Phase 1
• Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)Status unknownNCT05549284Phase 2
• Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCLStatus unknownNCT05498259Phase 2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• DDI Study of OrelabrutinibCompletedNCT05316857Phase 1
• A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderStatus unknownNCT05284175Not applicable
• A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaStatus unknownNCT05232149Phase 2
• A Study of Orelabrutinib in Patients With ITPStatus unknownNCT05124028Phase 1/2
• A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell LymphomaCompletedNCT05051891Phase 3
• A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSLCompletedNCT05036577Phase 1
• Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS LymphomaStatus unknownNCT05021770Phase 1/2
• A Clinical Trial of the Orelabrutinib in the Management of Refractory ITPStatus unknownNCT05020288Phase 2
• Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
• Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System LymphomaStatus unknownNCT04899427Phase 2
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
• ADME Study of [14C]ICP-022 in Healthy MalesCompletedNCT04441450Not applicable
• A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom MacroglobulinemiaCompletedNCT04440059Phase 2
• A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSLStatus unknownNCT04438044Phase 2
• A Study of ICP-022 in Patients With R/R DLBCLCompletedNCT04438005Phase 2
• A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT04305197Phase 1/2
• A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell LymphomaActive, not recruitingNCT04304040Phase 1/2
• A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesActive, not recruitingNCT04014205Phase 1/2
• A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Phase 2
• A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)CompletedNCT03494179Phase 1/2
• A Study to Evaluate ICP-022 in Patients With CLL/ SLLStatus unknownNCT03493217Phase 1/2
• A Phase I Study of ICP-022 in Healthy SubjectsCompletedNCT03189017Phase 1

← Orelabrutinib overview